Targeting CD137 enhances the efficacy of cetuximabHolbrook E. Kohrt(Stanford University), Ronald Levy(Stanford Medicine)Journal of Clinical InvestigationMay 15, 201410.1172/jci73014Cited by 161SaveCiteExport RISWatch citationsRelated PapersDistinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling|Blood|2016|80Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors|The Journal of Immunology|2023|3